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ASCO = American Society of Clinical Oncology; CI = confidence interval; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; DDPE = N,N-
diethyl-2(4-phenylmethyl-phenoxyethamine) hydrochloride; EGF = epidermal growth factor; ER = oestrogen receptor; FISH = fluorescence in situ
hybridization; MBC = metastatic breast cancer; RR = response rate; TTP = time to progression.
Available online http://breast-cancer-research.com/content/3/5/E004
Introduction
The goals of the ASCO annual meeting are to disseminate
the latest and most worthwhile research data emerging
from the fields of cancer prevention, detection, diagnosis,
prognosis and therapy. The majority of these topics were
covered to variable degrees in the field of breast cancer,
with educational sessions focusing on current controver-
sies and future directions, and scientific sessions filling in
the gaps between our current standards and the active
thrusts of research.
In the following text numbers in parentheses, in the format
‘(#XX)’, indicate the number of the abstract in the pro-
ceedings book for the meeting [1].
High-dose chemotherapy
Several randomized studies of standard versus high-dose
chemotherapy with stem cell support for either high-risk
adjuvant or metastatic therapy were presented. Three
studies in the adjuvant setting (#80, #81, #148) failed to
show a disease-free survival or overall survival advantage
at 5 years for high-dose chemotherapy compared with
standard or somewhat dose-escalated chemotherapy in
women with multiple positive nodes. One trial (Pegase
01; #102) reported better relapse-free survival for the
high-dose arm than the standard dose arm (71% versus
55%;  P < 0.003), suggesting that longer follow-up of
overall survival is required (the overall survival rates were
equivalent in the two arms at 3 years follow-up). In the
metastatic setting, the MA.16 study (#82) reported equiv-
alent overall survival for the 219 patients who were
randomly assigned to 2–4 additional cycles of anthra-
cycline- or taxane-based chemotherapy or to high-dose
chemotherapy after an objective response to standard
chemotherapy. In the same theme, several studies that
compared standard with increased dose intensity anthra-
cycline therapy (#146, #127) failed to show an advan-
tage for the latter strategy.
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Abstract
Key issues discussed at the breast cancer sessions of the 37th American Society of Clinical Oncology
(ASCO) meeting, 2001, included the following: breast cancer in the elderly; toxicity; updates on HER2
and use of trastuzumab (anti-HER2) in metastatic disease; and several early reports on novel
therapeutic strategies. As was stated by numerous speakers both at this and other meetings, and as
demonstrated by several abstracts, the use of predictive factors appears to be the most effective way
to enhance the efficacy of numerous therapies, both target specific and nonspecific.
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HER2 and Herceptin® (trastuzumab)
The prognostic and predictive role of HER2 continues to
be a hot topic in breast cancer.
Several studies (#85, #86) reported that benefit from
trastuzumab is confined to women with HER2 (c-erbB2)
gene amplification (assessed by fluorescence in situ
hybridization [FISH]), independent of immunohistochem-
istry results (3+ or 2+). Another abstract (#172) reported
similar efficacy of trastuzumab in oestrogen receptor (ER)-
positive and ER-negative metastatic breast cancer (MBC).
The predictive value of HER2 for chemotherapy sensitivity
was explored retrospectively in a number of randomized
trials in the adjuvant and metastatic settings. An Italian
group reported improved overall survival for HER2-positive
patients (assessed by immunohistochemistry) who
received anthracycline-based chemotherapy versus cyclo-
phosphamide, methotrexate, 5-fluorouracil (CMF)-based
chemotherapy, whereas for HER2-negative patients
overall survival was equivalent for both regimens (#89).
Another Italian trial reported a trend toward improved
overall survival for anthracycline over CMF therapy for
women with HER2-positive disease (hazard ratio 0.85,
95% confidence interval [CI] 0.27–2.71) but not for those
with HER2-negative disease (hazard ratio 1.64, 95% CI
0.85–3.14) (#133). The CIs crossed 1 in both groups,
however, suggesting equivalence.
In MBC, a trial that compared first-line epirubicin + pacli-
taxel with epirubicin + cyclophosphamide (#88) showed
equivalence for the two regimens among HER2-negative
(by FISH) patients and superior overall survival for epiru-
bicin + paclitaxel among HER2-positive patients
(P = 0.06). Another retrospective study (#181), however,
failed to demonstrate HER2 over-expression as a predic-
tive factor for response to taxanes. Serum HER2 level was
examined as a predictive marker of response to endocrine
therapy (#87). Among 153 women, the relative risk
(P = 0.0005), time to progression (TTP; P < 0.0001) and
overall survival (P < 0.0001) were lower in the group of 51
women (33%) with elevated levels of HER2, and for this
group there was no significant difference for megace and
letrozole. In the group without elevated HER2 levels, both
TTP (P = 0.017) and overall survival (P = 0.025) were
better for letrozole. Disease and patient characteristics,
which might also have influenced TTP and overall survival,
were not provided.
Other inhibitors of the HER family are in various stages of
development. Iressa® (ZD1839; AstraZeneca, Alderley
Park, Cheshire, UK), an epidermal growth factor (EGF)
receptor tyrosine kinase inhibitor, was explored in HER2-
over-expressing breast cancer cell lines (#8). Iressa®
almost entirely inhibited the phosphorylation (activation) of
HER2 at low concentrations. The degree of growth inhibi-
tion was greater with Iressa® than with Herceptin®
(trastuzumab; Genentech Inc, San Francisco, CA, USA)
and at high concentrations was able to inhibit growth in
Herceptin®-resistant cell lines. When given together, Her-
ceptin® and Iressa® were observed to induce apoptosis.
Another abstract (#282) reported inhibition of ERK1/2
activation (downstream of EGF receptor and c-erbB2) by
Iressa® in tamoxifen-resistant cells, which are known to
overexpress both EGF receptor and c-erbB2. Coupled
with this was a marked growth inhibitory effect, which was
not observed in wild-type MCF-7 cells (which are tamox-
ifen sensitive and do not have EGF receptor or c-erbB2
over-expression). Exploration of this drug with second-line
hormone therapy is needed to determine whether in vivo
effects parallel these promising findings.
Endocrine therapy
Adjuvant
A randomized trial of observation versus oophorectomy
plus tamoxifen in 709 premenopausal Vietnamese and
Chinese women (#99) reported substantial improvements
in disease-free survival (75% versus 58%; P = 0.006) and
overall survival (78% versus 70%; P = 0.04; 80% versus
58% among ER-positive patients) for the endocrine
therapy. A German study of CMF versus a luteinizing
hormone-releasing hormone analogue for 2 years in pre-
menopausal women with node-positive breast cancer
(#132) reported no difference in progression-free survival.
With only 2 years of follow-up, however, these data are
immature. Quality of life data from the Zebra trial (#138)
suggested better overall tolerance during the treatment
period for Zoladex® (goserelin; AstraZeneca) versus CMF
An ongoing question is the value of ovarian suppression
added to chemotherapy in premenopausal women; the
2000 Oxford overview (Meeting of the Early Breast
Cancer Trialists’ Collaborative Group, Oxford, UK, Sep-
tember 2000; unpublished data) suggests that there is
none. Subgroup analysis of the Zipp trial (#103), in which
2170 women were randomly assigned to receive gosere-
lin, tamoxifen or placebo, and could receive chemotherapy
at the investigator’s discretion, supported this finding.
Among women with ER-positive disease, the relative risk
for event-free survival of goserelin versus placebo was
0.74 for the group who had chemotherapy, and 0.86
among those with no chemotherapy, with confidence
intervals crossing 1 in both analyses. In contrast, an Italian
trial (#104) that randomly assigned women to two years of
goserelin plus tamoxifen versus no endocrine therapy fol-
lowing chemotherapy reported a hazard ratio for relapse of
0.57 for patients with ER-positive or unknown disease
who received the endocrine therapy (P = 0.02), although
no survival advantage has yet emerged (hazard ratio 0.86;
P = 0.52). In the small premenopausal subgroup of the
SWOG 7827 trial (#105), the addition of oophorectomy
to one year of CMF plus vincristine and predinsone did notc
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significantly alter the overall survival (P = 0.67). However,
100% of CMF plus vincristine and predinsone patients
developed amenorrhoea during chemotherapy (70% of
those younger than 40 years recovered menses).
The reverse question has also been asked in the post-
menopausal setting – does chemotherapy provide addi-
tional benefit over tamoxifen? The intergroup 0100 study
(#94), updated with 8 years of follow-up, continues to
show an advantage for cyclophosphamide, doxorubicin, 5-
fluorouracil with tamoxifen versus tamoxifen alone in terms
of disease-free survival (76% versus 67%; P = 0.0002)
and overall survival (84% versus 79%; P = 0.006).
Metastatic
Only a few studies of hormone therapy for MBC were
reported at this year’s ASCO meeting. Idoxifene, which
has fewer oestrogen agonist properties than tamoxifen,
was equivalent to tamoxifen in terms of response rate
(RR), clinical benefit, TTP, overall survival and adverse
events among postmenopausal women (#113). Exemes-
tane was associated with a high RR (41%), median dura-
tion of response and of clinical benefit of 18.4 and 16.6
months, respectively, and no adverse impact on serum
lipids when given as first-line therapy in a similar patient
population (#114, #167). The activity of the selective
oestrogen receptor modulator Arzoxifene® (LY-353381;
Eli Lilly & Co, Indianapolis, IN, USA) was low in tamoxifen
sensitive (RR 16%, clinical benefit 33% TTP 5.5 months)
and refractory patients (RR 7%, clinical benefit 12%, TTP
2.7 months; #178).
Novel therapeutic strategies for metastatic
breast cancer
A myriad of abstracts explored innovative treatment
approaches, including targeted therapies, new combina-
tions, and better patient selection based on predictive
factors.
A 96% positive predictive value and 94% sensitivity were
reported for 2-fluoro-2-deoxyglucose positron emission
tomography scanning among 119 patients with isolated
elevations in the tumour marker Ca15.3 (#165). Among
13 negative cases, seven were false negatives and six
were true negatives. This suggests that, where available,
positron emission tomography scanning may be a useful
tool for identifying occult disease.
Caelyx® (pegylated liposomal doxorubicin; Schering-
Plough, Levallois-Perret, France) was compared with
weekly vinorelbine or mitomycin plus vinblastine after
taxane failure in 301 MBC patients (#115). The RR, pro-
gression-free survival (2.9 versus 2.5 months; P = 0.11),
and median overall survival (10.4 versus 9.4 months;
P = 0.57) were equivalent. The proportion with prior
anthracycline therapy, which may have influenced
response to Caelyx®, was not given. Another group
reported enhanced efficacy of Caelyx® with local hyper-
thermia given for chest wall lesions, with a local RR of
60% among 20 evaluable patients (#184).
The antiangiogenic effects of chronic low dose oral
methotrexate and cyclophosphamide were explored
(#116); 52 out of 62 enrolled patients had prior chemother-
apy for MBC, and 20 had had at least two prior regimens.
The overall RR was 32%, but the progression-free survival
was a disappointing 2.8 months. A randomized comparison
of anthracycline alone or in combination with N,N-diethyl-
2(4-phenylmethyl-phenoxyethamine) hydrochloride (DDPE)
(#118), which in vitro enhances response to anthracy-
cline, reported equivalent RR and TTP (P = 0.3) but
improved overall survival (P = 0.02) for the combination
among 305 randomized patients. Potential explanations
for these results include chance, an imbalance in subse-
quent therapies or prognostic factors, or a sensitizing
effect of DDPE to subsequent chemotherapy.
A phase I study (#170) reported no maximum tolerated
dose (up to 1000 mg/day) and disease stabilization in 10
out of 14 evaluable patients treated with 2-methoxyoestra-
diol, an oestradiol metabolite that directly inhibits prolifer-
ating cells and has antiangiogenic activity. These early
results are promising and accrual is ongoing. Another
potentially active drug is Alimta® (LY231514, multi-tar-
geted antifolate; Ely Lilly & Co), an antifolate; administra-
tion of this agent resulted in a 10% RR and 38% stable
disease rate lasting 2.9–14.5 months (median
4.5 months) among 42 pretreated MBC patients (#194).
In contrast, a phase II trial of the anti-protein kinase C
oligonucleotide ISIS 3521 (#171) reported disappointing
results, with a median TTP of 1.3 months and only one out
of 15 patients free from progression at 4 months. Similarly
disappointing results were observed with the matrix metal-
loproteinase inhibitor Prinomastat® (Pfizer, LA Jolla, CA,
USA; 0% RR, TTP 8 weeks) and oral UFT plus leucovorin
following treatment with anthracyclines, taxanes, or both
(11% RR, TTP 72 days; #188, #186).
An oral vinorelbine formulation was examined as first-line
chemotherapy in 65 patients with locally advanced or
MBC at a dose of 60 mg/m2 per week, escalated to
80 mg/m2 per week if there was no significant neutropenia
(#185). Thus far, the RR by intention to treat is 31%; TTP
was not reported. Grade 3 toxicities included nausea
(6%), vomiting (8%), diarrhoea (6%) and grade 4 neu-
tropenia (14%).
Other novel therapies in the pipeline include epothilone, a
microtubulin stabilizer that is active in cell lines that
express multidrug resistant phenotypes (#269, #270); the
EGF receptor-selective tyrosine kinase inhibitor ZD1839
for treatment of tamoxifen-resistant disease (#282);
Available online http://breast-cancer-research.com/content/3/5/E0044
R115777, a farnesyl transferase inhibitor, as a single agent
and in combination with cytotoxic drugs and trastuzumab
(#322); the next generation bisphosphonate ibandronic
acid (#332); and numerous other specific inhibitors of the
EGF signalling pathways, cell-cycle regulators, angiogenic
mechanisms and drug-resistance mechanisms.
Conclusion
The majority of breast cancer abstracts at this year’s
ASCO meeting were clinical and therapeutic. Several key
points summarize the focus of breast cancer research at
this year’s meeting. 
Although not reviewed here, there was much focus on the
toxicity of adjuvant therapy. Randomized trials of high-
dose chemotherapy confirm a lack of advantage for this
modality over standard therapy in high-risk early or
metastatic settings. The question of the value of adding
ovarian ablation/suppression to chemotherapy in pre-
menopausal women remains unsettled. More retrospective
evidence points to a particular benefit from anthracyclines
in HER2-overexpressing tumours, and to benefit from
trastuzumab only in patients whose tumours have HER2
gene amplification by FISH, suggesting that FISH confir-
mation should be obtained when considering trastuzumab,
particularly if the immunohistochemistry score is 2+.
Iressa®, a EGF receptor tyrosine kinase receptor, had
favourable preliminary results in inhibiting growth of
HER2-overexpressing breast cancer cell lines. The use of
traditional cytotoxic drugs in different formulations or
dosing schedules met with variable success, and phase
I/II results for molecules such as protein kinase C oligonu-
cleotide and matrix metalloproteinases were on the whole
discouraging. It is ultimately by better defining ‘sensitive’
patient populations, through the use of predictive markers,
that we will make best use of our available and up and
coming cytotoxic and target-specific therapies.
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